EP2637661
Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
7.11.2011EP published:
20.12.2017EP application number:
11782111.6
EPO information:
European Patent Register
Max expiry date:
6.11.2031
Title:
Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
Timeline
Today
7.11.2011EP application
20.12.2017EP Publication
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
BRACHMANN, Saskia MariaAddress:
Basel, CH
Name:
FRITSCH, ChristineAddress:
Basel, CH
Name:
MAIRA, Sauveur-MichelAddress:
Basel, CH
Name:
SCHNELL, Christian RenéAddress:
Basel, CH
Name:
GARCIA-ECHEVERRIA, CarlosAddress:
Saint-Cloud, FR
Priority
Number:
411117 PDate:
8.11.2010Country:
US
Classification
Categories:
A61K 31/4439, A61K 31/517, A61K 39/395, A61K 45/06, A61P 35/00, C07K 16/32, A61K 39/00